A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein Occlusion

A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein Occlusion

Abstract Purpose The REal life assessmENt of safety And effeCTiveness of Razumab 2 (RE-ENACT 2) study evaluated the long-term effectiveness of biosimilar ranibizumab. We present the subgroup analysis of patients with retinal vein occlusion (RVO). Methods Data of patients who received pro re nata (PR...

Full description

Bibliographic Details
Main Authors: Shashikant Sharma, RE-ENACT 2 Study Investigators Group, Mujtaba Khan, Alok Chaturvedi
Format: Article
Language:English
Published: Adis, Springer Healthcare 2020-07-01
Series:Ophthalmology and Therapy
Subjects:
Anti-VEGF
Biosimilar ranibizumab
Razumab
Retinal vein occlusion
RVO
Online Access:https://doi.org/10.1007/s40123-020-00277-3

Internet

https://doi.org/10.1007/s40123-020-00277-3

Similar Items